These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25085214)

  • 1. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
    Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
    J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis.
    Durand KS; Guillaudeau A; Weinbreck N; DeArmas R; Robert S; Chaunavel A; Pommepuy I; Bourthoumieu S; Caire F; Sturtz FG; Labrousse FJ
    Mod Pathol; 2010 Apr; 23(4):619-28. PubMed ID: 20081802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
    Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
    Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular classification of low-grade diffuse gliomas.
    Kim YH; Nobusawa S; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Vital A; Mariani L; Stawski R; Watanabe T; De Girolami U; Kleihues P; Ohgaki H
    Am J Pathol; 2010 Dec; 177(6):2708-14. PubMed ID: 21075857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.
    Figarella-Branger D; Mokhtari K; Colin C; Uro-Coste E; Jouvet A; Dehais C; Carpentier C; Villa C; Maurage CA; Eimer S; Polivka M; Vignaud JM; Laquerriere A; Sevestre H; Lechapt-Zalcman E; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Viennet G; Adam C; Loussouarn D; Michalak S; Rigau V; Heitzmann A; Vandenbos F; Forest F; Chiforeanu D; Tortel MC; Labrousse F; Chenard MP; Nguyen AT; Varlet P; Kemeny JL; Levillain PM; Cazals-Hatem D; Richard P; Delattre JY;
    Brain Pathol; 2015 Jul; 25(4):418-28. PubMed ID: 25407774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
    Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
    J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
    Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H
    Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
    Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
    J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.
    Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M
    Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
    Mo H; Magaki S; Deisch JK; Raghavan R
    J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
    Lin AL; White M; Miller-Thomas MM; Fulton RS; Tsien CI; Rich KM; Schmidt RE; Tran DD; Dahiya S
    J Neurooncol; 2016 Dec; 130(3):529-533. PubMed ID: 27704386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
    Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular genetic evidence for subtypes of oligoastrocytomas.
    Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
    Ballester LY; Huse JT; Tang G; Fuller GN
    Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
    Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
    Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.